SUSPENSION LETTER - MAILED
mailed
on 17 Jul 2024
Last Applicant/ Owned by
855 2nd Street S.W.
Calgary, Alberta
CA
T2P4J8
Serial Number
97102047 filed on 01st Nov 2021
Registration Number
N/A
Correspondent Address
Charles G. Zug
Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP
SUITE 2300, IP DEPARTMENT
CHARLOTTE, NC 28202
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
ZYLORION
Medical and scientific research and product development in the field of psychedelics; medical and scientific research in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized commu Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Psychotherapy services; mental health therapy services for the treatment of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of information to others in the field of mental health; clinical mental health counselling services; compiling medical health information data in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Medical and scientific research and product development in the field of psychedelics; medical and scientific research in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; laboratory scientific and medical research in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; providing temporary use of non-downloadable computer software for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; compiling medical and scientific research data in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [041]
Education and Entertainment Services
Provision of training in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of education services, namely, providing courses of instruction, classes, seminars, workshops, and conferences in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; provision of training in the field of psychedelic medicines; provision of education services, namely, providing courses of instruction, classes, seminars, workshops, and conferences and training in the field of psychedelic medicines
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [035]
Advertising, Business & Retail Services
Data processing services of medical data relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; compiling medical data for business purposes relating to psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [031]
Natural Agricultural Products
Fresh edible mushrooms
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [029]
Meats and Processed Food Products
Dried edible mushrooms
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [009]
Computer & Software Products & Electrical & Scientific Products
Downloadable computer application software for mobile phones for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes; downloadable computer software for clinical interactions, scheduling appointments, submitting feedback, measuring feedback from biometrics, such as pulse and heart rate, and storing forms and questionnaires in connection with providing therapy services to individuals in the fields of psychiatric diseases, addiction disorders, anxiety disorders, psychological trauma, physical trauma, chronic pain, cognitive diseases, neuropsychiatric disorders, sleep related disorders, mental health problems experienced by indigenous and other marginalized communities, and covid-19 symptoms and syndromes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Psychedelic medicines for the treatment of psychiatric diseases, namely, mood disorders, depression, mood and emotional instability disorders; psychedelic medicines for the treatment of addiction disorders, namely, alcohol abuse, drug abuse, eating disorders, gambling addiction and sex addiction; psychedelic medicines for the treatment of anxiety disorders, namely, social anxiety, generalized anxiety and panic attack disorder; psychedelic medicines for the treatment of psychological trauma, namely, post-traumatic stress disorder, occupational stress injury, bullying, emotional trauma, physical trauma, work trauma, family violence and grief; psychedelic medicines for the treatment of physical trauma, namely, post-burn injury, post-spinal-cord injury, adult post-amputation, post-brain injury and post-stroke; psychedelic medicines for the treatment of chronic pain, namely, migraines, chronic back pain and chronic arthritis; psychedelic medicines for the treatment of cognitive diseases, namely, cognitive deterioration, early dementia and age-associated memory impairment; psychedelic medicines for the treatment of neuropsychiatric disorders, namely, adult fetal alcohol spectrum disorder, adult attention deficit disorder, adult autism, post-stroke symptoms, multiple sclerosis and Parkinson's disease; psychedelic medicines for the treatment of sleep related disorders, namely, chronic fatigue syndrome, fatigue and insomnia; psychedelic medicines for the treatment of mental health problems experienced by indigenous and other marginalized communities; psychedelic medicines for the treatment of covid-19 symptoms and syndromes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97102047
Mark Type
No Service Mark
Attorney Docket Number
No 070840/09000
44D Filed
Yes
44D Current
Yes
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 17th Jul 2024 | LETTER OF SUSPENSION E-MAILED |
| 17th Jul 2024 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| 17th Jul 2024 | SUSPENSION LETTER WRITTEN |
| 16th Jul 2024 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| 16th Jul 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 16th Jul 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 17th Apr 2024 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| 17th Apr 2024 | INQUIRY TO SUSPENSION E-MAILED |
| 17th Apr 2024 | SUSPENSION INQUIRY WRITTEN |
| 19th Oct 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |